Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Other Working Capital Changes (2018 - 2025)

Zevra Therapeutics' Other Working Capital Changes history spans 11 years, with the latest figure at -$399000.0 for Q4 2025.

  • For Q4 2025, Other Working Capital Changes fell 121.38% year-over-year to -$399000.0; the TTM value through Dec 2025 reached $2.9 million, up 252.46%, while the annual FY2025 figure was $2.9 million, 263.54% up from the prior year.
  • Other Working Capital Changes reached -$399000.0 in Q4 2025 per ZVRA's latest filing, down from $2.6 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $2.6 million in Q3 2025 to a low of -$2.7 million in Q3 2021.
  • Average Other Working Capital Changes over 5 years is $198000.0, with a median of -$97500.0 recorded in 2022.
  • The largest YoY upside for Other Working Capital Changes was 3349.32% in 2021 against a maximum downside of 3646.58% in 2021.
  • A 5-year view of Other Working Capital Changes shows it stood at $964000.0 in 2021, then tumbled by 123.76% to -$229000.0 in 2022, then skyrocketed by 175.98% to $174000.0 in 2023, then soared by 972.41% to $1.9 million in 2024, then crashed by 121.38% to -$399000.0 in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Other Working Capital Changes are -$399000.0 (Q4 2025), $2.6 million (Q3 2025), and $936000.0 (Q2 2025).